内科理论与实践
內科理論與實踐
내과이론여실천
JOURNAL OF INTERNAL MEDICINE CONCEPTS & PRACTICE
2009年
4期
282-284
,共3页
汤荟冬%潘萌%任谊%陈生弟
湯薈鼕%潘萌%任誼%陳生弟
탕회동%반맹%임의%진생제
系统性红斑狼疮%中枢神经系统%糖皮质激素%环磷酰胺
繫統性紅斑狼瘡%中樞神經繫統%糖皮質激素%環燐酰胺
계통성홍반랑창%중추신경계통%당피질격소%배린선알
Systemic lupus erythematosus%Central nervous system%Cortical steroid%Cyclophosphamide
目的:探讨系统性红斑狼疮(SLE)伴神经系统病变的临床特征.方法:回顾性分析41例伴中枢神经系统损害的SLE患者(女38例,男3例)的临床特点、辅助检查结果以及治疗效果.结果:SLE中枢神经系统损害以弥漫性症状(51.2%)为多见,其次为局灶性(22.0%)、抽搐发作(12.2%)和其他(14.6%);29例患者中枢神经系统症状发生在SLE病后3年内,占71.7%;32例脑电图(EEG)检查的患者中27例有异常(84.3%),其中21例弥漫性症状患者中EEG异常20例(95.2%);22例局灶性症状患者中13例(59.1%)磁共振成像(MRI)检查异常.21例伴蛋白尿患者同时接受糖皮质激素和环磷酰胺治疗,余20例患者接受单纯糖皮质激素治疗,前者疗效可能优于后者(X2=5.91,P=0.05).结论:SLE神经系统损害以颅内弥漫性损害常见,EEG检查有助于早期弥漫性症状患者的诊断,糖皮质激素联合环磷酰胺治疗伴有中枢神经系统损害的SLE,其疗效可能优于单一糖皮质激素治疗.
目的:探討繫統性紅斑狼瘡(SLE)伴神經繫統病變的臨床特徵.方法:迴顧性分析41例伴中樞神經繫統損害的SLE患者(女38例,男3例)的臨床特點、輔助檢查結果以及治療效果.結果:SLE中樞神經繫統損害以瀰漫性癥狀(51.2%)為多見,其次為跼竈性(22.0%)、抽搐髮作(12.2%)和其他(14.6%);29例患者中樞神經繫統癥狀髮生在SLE病後3年內,佔71.7%;32例腦電圖(EEG)檢查的患者中27例有異常(84.3%),其中21例瀰漫性癥狀患者中EEG異常20例(95.2%);22例跼竈性癥狀患者中13例(59.1%)磁共振成像(MRI)檢查異常.21例伴蛋白尿患者同時接受糖皮質激素和環燐酰胺治療,餘20例患者接受單純糖皮質激素治療,前者療效可能優于後者(X2=5.91,P=0.05).結論:SLE神經繫統損害以顱內瀰漫性損害常見,EEG檢查有助于早期瀰漫性癥狀患者的診斷,糖皮質激素聯閤環燐酰胺治療伴有中樞神經繫統損害的SLE,其療效可能優于單一糖皮質激素治療.
목적:탐토계통성홍반랑창(SLE)반신경계통병변적림상특정.방법:회고성분석41례반중추신경계통손해적SLE환자(녀38례,남3례)적림상특점、보조검사결과이급치료효과.결과:SLE중추신경계통손해이미만성증상(51.2%)위다견,기차위국조성(22.0%)、추휵발작(12.2%)화기타(14.6%);29례환자중추신경계통증상발생재SLE병후3년내,점71.7%;32례뇌전도(EEG)검사적환자중27례유이상(84.3%),기중21례미만성증상환자중EEG이상20례(95.2%);22례국조성증상환자중13례(59.1%)자공진성상(MRI)검사이상.21례반단백뇨환자동시접수당피질격소화배린선알치료,여20례환자접수단순당피질격소치료,전자료효가능우우후자(X2=5.91,P=0.05).결론:SLE신경계통손해이로내미만성손해상견,EEG검사유조우조기미만성증상환자적진단,당피질격소연합배린선알치료반유중추신경계통손해적SLE,기료효가능우우단일당피질격소치료.
Objective To investigate the clinical characteristics of central nervous system (CNS) impairment in patients with systemic lupus erythematosus (SLE). Methods The clinical characteristics of 41 SLE patients with central nervous system impairment (38 female, 3 male) were analyzed retrospectively. Results Diffuse clinical symptom presentation was the most common manifestation (51.2%) in SLE patients with central nervous system impairment, followed by focal clinical symptom presentation (22.0%), seizure presentation (12.2%), and other clinical symptom presentation (14.6%). Central nervous system impairment occurred in 29 (71.7%) patients within 3 years after onset of SLE. Twenty-seven (84.3%) of the 32 cases performed electroencephalography had abnormal electroencephalogram (EEG). Twenty (95.2%) of 21 patients with diffused clinical symptom presentation showed abnormal EEG, and 13 (59.1%) of 22 patients with focal clinical symptom presentation showed abnormal MRI imaging. Twenty-one patients accompanying albuminuria were treated with immune inhibitor (cyclophosphamide, CTX) combined with cortical steroid, the rest of 20 patients were treated with cortical steroid only. The curative effects in the former therapy might be better than that in the later(X<'2>=5.91, P=0.05). Conclusions Diffuse clinical symptom presentation is a common manifestation in SLE patients associated with central nervous system impairment. EEG examination is helpful for the early diagnosis in the patients. In SLE patients associated with central nervous system impairment, cortical steroid combined with cyclophosphoamide is more efficacious than cortical steroid alone.